Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nalbuphine + Long dan xie gan tang is a drug-herb combination investigated for potential pharmacokinetic and pharmacodynamic interactions. Nalbuphine is a semi-synthetic opioid analgesic that functions as a kappa-opioid receptor agonist and a mu-opioid receptor antagonist. Long dan xie gan tang (LDXGT), also known as Gentiana Decoction to Drain the Liver, is a traditional Chinese herbal formula typically used to treat conditions associated with damp-heat in the liver and gallbladder. The Tri-Service General Hospital conducted Phase 1 clinical research to evaluate how the co-administration of LDXGT affects the safety, metabolism, and efficacy of nalbuphine in healthy subjects. This study specifically aimed to identify herb-drug interactions that might alter the clinical profile of the opioid analgesic when used alongside traditional herbal medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nalbuphine + Long dan xie gan tang.